Can you provide the upcoming earnings date for REVIVA PHARMACEUTICALS HOLDI?
REVIVA PHARMACEUTICALS HOLDI (RVPH) will report earnings on 2026-03-23, after the market close.
REVIVA PHARMACEUTICALS HOLDI (RVPH) Forecast, Price Target & Analyst Ratings
NASDAQ:RVPH • US76152G1004
Current stock price
0.893 USD
+0.09 (+11.62%)
At close:
0.9 USD
+0.01 (+0.78%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVIVA PHARMACEUTICALS HOLDI (RVPH).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$1.19
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.89 to mean target of N/A, Based on 12 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
-3.69%
3 Months
-6.83%
Price Target Summary
The average price target has been revised downward by 6.83% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.67%
RVPH was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about RVPH.
In the previous month the buy percentage consensus was at a similar level.
RVPH was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-05 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2026-01-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-29 | Chardan Capital | Initiate | Buy |
| 2025-09-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-15 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2025-08-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-18 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-08-15 | Maxim Group | Maintains | Buy -> Buy |
| 2025-06-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-10 | Roth MKM | Initiate | Buy |
| 2025-01-10 | Maxim Group | Upgrade | Hold -> Buy |
| 2024-11-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-09-23 | EF Hutton | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$1.19
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 60.33%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-1,649.92%
EPS (3 Months)
-1,284.11%
Next Earnings Summary
RVPH is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -1.19 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 269.13% | N/A 95.92% | N/A 57.12% | N/A 37.16% | N/A 28.31% | |||||||
| EBITDA YoY % growth | N/A | -724.1K | -10.105M -1,295.46% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -152.8K | -724.7K -374.28% | -10.105M -1,294.30% | -28.229M -179.37% | -39.504M -39.94% | -30.799M 22.04% | N/A 21.05% | N/A -27.13% | N/A -54.97% | N/A 59.25% | N/A 723.99% | N/A 144.70% | N/A 74.73% | N/A 41.82% | N/A 31.74% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -0.56 83.85% | -25.00 -4,364.29% | -32.80 -31.20% | -18.20 44.51% | N/A 60.99% | N/A 43.01% | N/A -31.09% | N/A 98.65% | N/A 942.86% | N/A 98.31% | N/A 47.01% | N/A 27.91% | N/A 24.09% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.19 60.33% | -1.07 58.81% | -1.12 53.25% | -1.17 2.25% | -1.22 -2.86% | -1.84 -71.43% | -1.84 -63.64% | -2.04 -73.91% | -2.04 -66.67% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.486M -19.11% | -7.138M -9.17% | -7.578M -24.78% | -8.403M -108.52% | -9.271M -23.85% | -14.217M -99.17% | -14.835M -95.76% | -16.071M -91.26% | -16.689M -80.01% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.55%
EPS Next 5 Year
15.25%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
REVIVA PHARMACEUTICALS HOLDI / RVPH Forecast FAQ
What are the consensus estimates for REVIVA PHARMACEUTICALS HOLDI (RVPH) next earnings?
The consensus EPS estimate for the next earnings of REVIVA PHARMACEUTICALS HOLDI (RVPH) is -1.19 USD and the consensus revenue estimate is 0 USD.